Atara Biotherapeutics Files 8-K Report
Ticker: ATRA · Form: 8-K · Filed: May 16, 2025 · CIK: 1604464
| Field | Detail |
|---|---|
| Company | Atara Biotherapeutics, INC. (ATRA) |
| Form Type | 8-K |
| Filed Date | May 16, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: ATRA
TL;DR
ATRA filed an 8-K, likely with financial updates. Keep an eye out for details.
AI Summary
On May 14, 2025, Atara Biotherapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and other significant corporate activities. No specific financial figures or new material events were detailed in the provided excerpt.
Why It Matters
This filing signals that Atara Biotherapeutics is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard disclosure document (8-K) without immediate negative or positive news, thus posing a low immediate risk.
Key Players & Entities
- Atara Biotherapeutics, Inc. (company) — Registrant
- May 14, 2025 (date) — Date of earliest event reported
- 1280 Rancho Conejo Blvd (location) — Principal Executive Offices Address
- Thousand Oaks, California (location) — Principal Executive Offices City and State
- 91320 (location) — Principal Executive Offices Zip Code
- (805) 623-4211 (phone_number) — Registrant's Telephone Number
FAQ
What specific "Other Events" are being reported by Atara Biotherapeutics in this 8-K filing?
The provided excerpt does not detail the specific "Other Events" being reported; it only lists the item category.
What is the significance of the "Financial Statements and Exhibits" being listed as an item in this 8-K?
This indicates that the filing may include updated financial information or exhibits relevant to the company's operations or financial condition.
When was the earliest event reported in this Form 8-K?
The earliest event reported is dated May 14, 2025.
What is Atara Biotherapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 1280 Rancho Conejo Blvd, Thousand Oaks, California, 91320.
What is the SEC file number for Atara Biotherapeutics, Inc.?
The SEC file number for Atara Biotherapeutics, Inc. is 001-36548.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 16, 2025 regarding Atara Biotherapeutics, Inc. (ATRA).